Sign In
Buy BMY
$56.60
+1.88 (+3.44%)
At Close: Jun 04, 2026
Bristol Myers Squibb sues federal government over Medicare drug negotiations: report
05:02pm, Friday, 16'th Jun 2023
Bristol Myers Squibb Co. BMY, +2.30% is suing the federal government over Medicare's drug price negotiation program, CNBC reported late Friday. The company has asked the court to declare the program u
Bristol Myers Squibb sues Biden administration over Medicare drug negotiations
04:46pm, Friday, 16'th Jun 2023
Bristol Myers Squibb on Friday sued the Biden administration over Medicare's new powers to negotiate drug prices, the third such lawsuit to be filed against the program in a matter of days.
Bristol Myers (BMY) Gets FDA Nod for Data Addition to Camzyos
03:21pm, Friday, 16'th Jun 2023
Bristol Myers (BMY) receives FDA approval for additional data to be added to the label of the heart drug Camzyos.
Bristol Myers Squibb (BMY) Flat As Market Gains: What You Should Know
07:05pm, Tuesday, 13'th Jun 2023
In the latest trading session, Bristol Myers Squibb (BMY) closed at $64.76, marking no change from the previous day.
Bristol-Myers Squibb Company (BMY) Presents at Goldman Sachs 44th Annual Global Healthcare Conference (Transcript)
02:55pm, Tuesday, 13'th Jun 2023
Bristol-Myers Squibb Company (NYSE:BMY ) Goldman Sachs 44th Annual Global Healthcare Conference June 13, 2023 11:40 AM ET Company Participants Lynelle Hoch - SVP, Global Cell Therapy Franchise Roland
Nicholas Ward's Dividend Growth Portfolio: April And May Review
07:50am, Tuesday, 13'th Jun 2023
My passive income stream increased by 25.59% YoY in April 2023 and 40.02% YoY in May 2023, with a year-to-date growth of 29.99%. I have been taking advantage of high yields on money market funds and s
This Drug Candidate Could Be a Winner for Bristol Myers
07:45am, Monday, 12'th Jun 2023
Repotrectinib could be an impactful treatment for patients with a certain type of lung cancer. The indication could haul in $200 million annually for the company in the United States alone.
DCLA's Sarat Sethi reveals the best undervalued stocks to buy right now
08:15am, Thursday, 08'th Jun 2023
Sarat Sethi, DCLA managing partner and portfolio manager, joins 'Squawk Box' to discuss the latest market trends, his top undervalued stock picks, and more.
Bristol-Myers Squibb Company (BMY) Presents at 2023 Virtual ASCO Investor Event Conference (Transcript)
02:02pm, Tuesday, 06'th Jun 2023
Bristol-Myers Squibb Company (NYSE:BMY ) 2023 Virtual ASCO Investor Event Conference June 6, 2023 8:00 AM ET Company Participants Tim Power - Investor Relations Samit Hirawat - Chief Medical Officer A
Bristol Myers (BMY) Announces Upbeat Data From NSCLC Study
11:25am, Monday, 05'th Jun 2023
Bristol Myers (BMY) reports encouraging four-year clinical efficacy results from its lung cancer study upon treatment with the combination immunotherapy of Opdivo plus Yervoy.
Bristol Myers Squibb: Take The Red Pill
08:05am, Monday, 05'th Jun 2023
Bristol Myers Squibb (BMY) is an undervalued pharmaceutical stock with strong positioning in cardiovascular, oncology, and immunology sectors. BMY has a strong balance sheet, high margins, and a pipel
3 Dividend Stocks You Can Buy Without Any Hesitation
06:14am, Saturday, 03'rd Jun 2023
Bristol Myers Squibb is a biopharmaceutical industry stalwart that pays a high dividend. Gilead Sciences' valuation is cheap, and its dividend continues to grow.
Bristol Myers Squibb CEO on cancer drug pipeline
02:25pm, Friday, 02'nd Jun 2023
Dr. Giovanni Caforio, Bristol Myers Squibb CEO, joins 'The Exchange' to discuss the ASCO Annual Cancer Conference, America's growing cancer drug shortage, and progress being made on advancing cancer t
BioNTech Surges On This Promising Update In Its Bid To Take On Bristol Myers In Lung Cancer Treatment
11:11am, Friday, 02'nd Jun 2023
BioNTech said Friday almost a third of patients with a hard-to-treat form of lung cancer responded to its treatment — and BNTX stock popped.
Bristol Myers (BMY) Loses 10.5% Year-to-Date: What Lies Ahead?
01:50pm, Thursday, 01'st Jun 2023
Bristol-Myers' (BMY) top drugs, Revlimid and Eliquis, face challenges. It remains to be seen if the approval of new drugs can fuel growth and offset declines.
